28 results on '"Kumar, Shiva Senthil"'
Search Results
2. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG)
3. Vorinostat, temozolomide or bevacizumab with irradiation and maintenance BEV/TMZ in pediatric high-grade glioma: A Children’s Oncology Group Study
4. Preclinical pediatric brain tumor models for immunotherapy: Hurdles and a way forward.
5. DIPG-06. PRECLINICAL EVALUATION OF A NOVEL ACVR1 INHIBITOR IN DIFFUSE INTRINSIC PONTINE GLIOMAS
6. DIPG-05. EVALUATION OF TELOMERE-MODIFYING COMPOUND THIO AS A RADIOSENSITIZER AND IMMUNOMODULATOR TO TREAT DIPG
7. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study
8. DIPG-12. Induced mitotic abnormalities associated with BMI-1 modulation sensitize diffuse intrinsic pontine glioma cells to ionizing radiation
9. DIPG-16. Evaluation of myeloid component of DIPG microenvironment
10. EPCT-06. Phase I study of ribociclib and everolimus post-radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG): Updated report from the COllaborative Network for NEuro-Oncology Clinical Trials (CONNECT)
11. DIPG-11. DIPGs show robust MHC class I expression but low lymphoid and high myeloid infiltration partly reversible by DNA methyltransferase inhibition
12. DIPG-13. Immune profiling by RNA-seq deconvolution and single-cell sequencing reveal myeloid cell enrichment in DIPG tumor microenvironment
13. EPCT-05. Phase Ib study of unesbulin (PTC596) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG): A report from the COllaborative Network for NEuro-Oncology Clinical Trials (CONNECT)
14. Limitations of radiosensitization by direct telomerase inhibition to treat high-risk medulloblastoma.
15. OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes
16. DIPG-21. INDUCTION OF MITOTIC ABNORMALITIES AND BMI-1 MODULATION TO TREAT DIFFUSE INTRINSIC PONTINE GLIOMA
17. EPCT-19. A PHASE I STUDY OF RIBOCICLIB AND EVEROLIMUS FOLLOWING RADIATION THERAPY IN CHILDREN WITH NEWLY DIAGNOSED NON-BIOPSIED DIFFUSE PONTINE GLIOMAS (DIPG) AND RB+ BIOPSIED DIPG AND HIGH GRADE GLIOMAS (HGG)
18. Phase I study of ribociclib and everolimus in children with newly diagnosed DIPG and high-grade glioma: A CONNECT pediatric neuro-oncology consortium report.
19. THER-10. TELOMERE TARGETING BASED-THERAPIES TO TREAT THERAPY-RESISTANT PEDIATRIC BRAIN TUMORS
20. THER-11. BMI-1 MODULATION IMPAIRS DNA DAMAGE RESPONSE AND SENSITIZES DIPG CELLS TO IONIZING RADIATION
21. DIPG-13. SENSITIVITY OF DIPG CELLS TO BMI-1 MODULATOR PTC596 IS INDEPENDENT OF EZH2 ACTIVITY
22. EAPH-02. TARGETING 6-THIO-dG-INDUCED G2/M ARREST TO ERADICATE BRAIN TUMOR CELL SURVIVORS
23. DIPG-18. VALIDATION OF BMI-1 AS A THERAPEUTIC TARGET IN DIFFUSE INTRINSIC PONTINE GLIOMA
24. TMOD-10. INTRACRANIAL PATIENT-DERIVED XENOGRAFT FROM A PEDIATRIC GLIOBLASTOMA RETAINS MOLECULAR CHARACTERISTICS AND GROWTH PATHWAYS
25. DIPG-17. TELOMERE-INDUCED DAMAGE AS A NOVEL APPROACH TO TREAT DIFFUSE INTRINSIC PONTINE GLIOMA
26. BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma
27. Erratum: Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics
28. Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.